QuidelOrtho

QuidelOrtho Corporation was strategically formed in 2022 through the massive, highly complementary merger of two undisputed diagnostic industry leaders: Quidel Corporation (a legendary pioneer in rapid point-of-care testing) and Ortho Clinical Diagnostics (a global titan in clinical laboratory and transfusion medicine). This powerful combination successfully created a comprehensive, end-to-end diagnostics powerhouse uniquely capable of serving the entire healthcare continuum—from the massive, highly automated centralized hospital laboratory down to the decentralized urgent care clinic or even the patient’s home.

Quidel is globally renowned for its rapid lateral flow tests and the highly successful Sofia® fluorescent immunoassay platform, which proved absolutely indispensable for rapid influenza, strep, and COVID-19 testing globally. Ortho, on the other hand, brings decades of absolute global dominance in immunohematology (blood typing and screening), actively ensuring the safety of the global blood supply with their renowned ORTHO VISION® analyzers, alongside robust, high-throughput clinical chemistry platforms (the VITROS® series).

By officially merging these capabilities, QuidelOrtho offers a unique, highly resilient diagnostic portfolio. Their corporate strategy focuses intensely on democratizing diagnostic access, ensuring that highly accurate testing is available immediately at the point of care while also aggressively maintaining the rigorous, high-throughput standards required by central blood banks and hospitals.